Streetbeat News

Analyst Ratings

HLMN

Barclays analyst Matthew Bouley maintains an Overweight rating on Hillman Solns (NASDAQ:HLMN) and raises the price target from $10 to $11.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2023 | 10:54 am

GMAB

HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a 'Buy' rating on Genmab (NASDAQ:GMAB) and maintained a price target of $51.

Portfolio Pulse from richadhand@benzinga.com

August 15, 2023 | 10:53 am

THG

Keefe, Bruyette & Woods analyst Meyer Shields has maintained a 'Market Perform' rating on Hanover Insurance Gr (NYSE:THG) but lowered the price target from $124 to $120.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2023 | 10:53 am

CLSD

HC Wainwright & Co. analyst Yi Chen has reiterated a 'Buy' rating on Clearside Biomedical (NASDAQ:CLSD) and maintained a $6 price target.

Portfolio Pulse from richadhand@benzinga.com

August 15, 2023 | 10:52 am

WDAY

Jefferies analyst Brent Thill has maintained a 'Buy' rating on Workday (NASDAQ:WDAY) and raised the price target from $250 to $275.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2023 | 10:52 am

MOND

Mondee Hldgs (NASDAQ:MOND) reported Q2 adjusted losses of $(0.05) per share, beating the analyst consensus estimate of $(0.10) by 50%. The company also reported quarterly sales of $56.77 million, beating the analyst consensus estimate of $55.44 million by 2.40%. This represents a 32.95% increase over sales from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2023 | 10:52 am

MNDY

Jefferies analyst Brent Thill maintains a Hold rating on Monday.Com (NASDAQ:MNDY) and raises the price target from $150 to $180.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2023 | 10:50 am

ABSI

HC Wainwright & Co. analyst Swayampakula Ramakanth has reiterated a 'Buy' rating on Absci (NASDAQ:ABSI) and maintained a $4 price target.

Portfolio Pulse from richadhand@benzinga.com

August 15, 2023 | 10:50 am

LPTX

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains a 'Buy' rating on Leap Therapeutics and raises the price target from $2.5 to $7.

Portfolio Pulse from richadhand@benzinga.com

August 15, 2023 | 10:50 am

NOGN

Jefferies analyst Samad Samana has maintained a 'Hold' rating on Nogin (NASDAQ:NOGN) and raised the price target from $0.5 to $1.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2023 | 10:50 am